BioForge - The future of peptide manufacturing
Scalable fermentation-based manufacturing for peptide therapeutics containing non-canonical amino acids. Replacing solid-phase peptide synthesis with sustainable biomanufacturing.
Built for the coming scale gap
Therapeutic peptides are ramping fast, and the industry is heading for a real capacity crunch by 2030. BioForge is designed to help fill that gap with fermentation-based production.
High-fidelity ncAA peptides, including multi-ncAA
We can place up to three different non-canonical amino acids in a peptide, with site-specific control and good fidelity, including functional handles for conjugation.
Works on proven fermentation infrastructure
This runs on standard E. coli fermentation setups and scales from mg to kg using familiar manufacturing approaches, rather than bespoke chemistry-heavy processes.
Sustainable biomanufacturing
Compared with SPPS, fermentation avoids toxic solvent-heavy workflows and can dramatically cut hazardous waste and carbon footprint, which matters more than ever for pharma.
Competitive landscape
How BioForge compares to existing manufacturing approaches
| Feature | Traditional SPPS | Bio Competitors | Constructive.bio |
|---|---|---|---|
| ncAA Incorporation | Limited by chemistry | Up to 1 | Up to 3, multiple instances |
| Product Size | ~50 AAs max | Peptides & proteins | Any length |
| Phage resistance | N/A | Susceptible | Inherently resistant |
| Scalability | Medium | High | mg to kg scale |
| Titre Performance | N/A | Variable | Industrial titres |
ncAA Incorporation
Product Size
Phage resistance
Scalability
Titre Performance
Market opportunity
GLP-1 Market Today
Projected by 2030
The GLP-1 market for diabetes and obesity is driving unprecedented demand for peptides with enabling properties delivered with non-canonical amino acids. Constructive BioForge removes bottlenecks and opens up scalable, more sustainable manufacturing for these valuable assets, plus other peptides and proteins of any length.
How it works
From design to delivery: sustainable peptide manufacturing
Unmatched structural diversity
From short peptides to long proteins, linear to cyclic, standard to exotic backbones
Multiple ncAAs, precise positioning
2 different ncAAs, each at 2 positions
Linear or cyclic structures
N-term
C-term
ncAA chemistry enables cyclization
Complete backbone flexibility
Standard peptide backbone
Enhanced stability, reduced flexibility
Extended backbone with novel properties
Frequently Asked Questions
How does BioForge manufacture peptides differently from SPPS?
BioForge uses genome-recoded E. coli fermentation instead of solid-phase peptide synthesis (SPPS). A gene encoding the target peptide — including codons for non-canonical amino acids — is expressed in recoded strains that incorporate ncAAs ribosomally during standard fermentation. This replaces iterative chemical coupling cycles with biological production in stainless-steel bioreactors.
What scale can BioForge achieve for peptide production?
BioForge scales from milligram discovery quantities to kilogram commercial supply using standard biopharma fermentation infrastructure. Because production relies on exponential cell growth rather than linear chemical coupling, scale-up follows established fermentation economics — a significant cost advantage over SPPS at GLP-1-class demand volumes.
Can BioForge produce peptides with multiple non-canonical amino acids?
Yes. BioForge can incorporate up to three different non-canonical amino acids in a single peptide at defined positions. This includes orthogonal click-chemistry handles, backbone-modified residues for protease resistance, and lipophilic ncAAs for half-life extension — all in one molecule with high translational fidelity.
How does BioForge reduce the environmental impact of peptide manufacturing?
BioForge replaces the organic solvents used in SPPS (DMF, NMP, DCM) with aqueous fermentation, eliminating thousands of litres of hazardous waste per batch. The platform uses renewable sugar feedstocks, operates at moderate temperatures, and reduces the carbon footprint of peptide manufacturing by an estimated 80–90% compared to equivalent SPPS production.
What peptide lengths and structures can BioForge produce?
BioForge has no practical peptide length limit — it can produce short peptides, long polypeptides, and full-length proteins. The platform also supports cyclic peptides via ncAA-mediated macrocyclisation, and diverse backbone chemistries including α,α-disubstituted and β-amino acid residues that are difficult or impossible to incorporate via SPPS.
Ready to transform manufacturing?
Partner with us to access our revolutionary peptide manufacturing platform.
Contact us →